IRVING, Texas--(BUSINESS WIRE)--Technology advances for coronary, peripheral and neuro vascular devices continue to drive changes to the market and non-clinical hospital staff must stay informed. To meet the needs of non-clinical staff, Vizient, Inc. has published a new edition of its Technology Watch.
“The cardiovascular, peripheral vascular and neuro endovascular market is dynamic with revolutionary devices securing FDA approval. Adding to the dynamics is the changing payer model which will have significant impact on the hospital and medical device utilization,” said Craig Lukowski, director, Physician Preference Contract Services.
Insights from the new issue of Technology Watch include:
- Drug-coated balloons have emerged as one of the fastest-growing products in peripheral vascular. Strong U.S. growth is forecast to continue based on positive clinical data, outpatient reimbursement and a new technology add-on payment for inpatient procedures.
- The coronary stent market will be at the forefront of change in the coming year. The need to utilize medical devices that can increase the chances of keeping patients out of the hospital longer and demonstrate to payers improved economic/outcomes data are driving them to look at product procurement differently.
- Stroke therapy is emerging as the next vascular frontier. Strong physician preference and supplier relationships make pricing control challenging.
Understanding what products are coming allows health care organizations to appropriately plan for their use. “Vizient’s Technology Watch gives non-clinical staff the information they need to talk with physicians and clinicians about new products. This type of dialogue is important as it facilitates collaboration on use, clinical benefits and cost prior to a device showing up at the hospital,” said Lukowski.
About Vizient, Inc.
Vizient, Inc., the largest member-owned health care company in the country, is dedicated to serving members and customers through innovative data-driven solutions, expertise and collaborative opportunities that lead to improved patient outcomes and lower costs. Vizient’s diverse membership and customer base includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute health care providers and represents almost $100 billion in annual purchasing volume. The Vizient brand identity represents the integration of VHA Inc., University HealthSystem Consortium and Novation, which combined in 2015, as well as the recently acquired MedAssets’ Spend and Clinical Resource Management (SCM) segment, which includes Sg2. In 2016, Vizient received a World’s Most Ethical Company designation from the Ethisphere Institute. Vizient’s headquarters are in Irving, Texas, with locations in Chicago and other cities across the United States. Please visit www.vizientinc.com as well as our newsroom, blog, Twitter, LinkedIn and YouTube pages for more information about the company.